Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

WiSA Technologies, Inc. and the WiSA Technologies, Inc. logo, the WiSA ... Division of its parent company, Datavault AI, Inc., is dedicated to advancing immersive, high-quality, and wireless ...

Rumours of a Hi ... res service “is coming at some point.” But it’s still not here as of early 2025. The service has been much delayed considering it was first trailed in 2021. There was a lot of ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00. The company has ...

Biogen Inc. CEO ... that takes all of the company’s cash flow and that there is an interest in building the pipeline with multiple assets. “If we could do more HI-Bios, that’s probably ...

The stock's fall snapped a seven-day winning streak.

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...

[Applied Science] shows how you can add an array of tiny LEDs and some compute power to produce high-resolution images — higher than you can get with the microscope on its own. The idea is to ...

If the pathway to Alzheimer’s diagnosis and treatment does not begin to improve rapidly, Biogen’s high-risk investment ... and we have a mixed view on the company's distribution strategy.